LYNBROOK, N.Y., June 2, 2017 /PRNewswire/ -- BioSpecifics
Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that
originated and continues to develop collagenase based-therapies
with a first in class collagenase-based product marketed as
XIAFLEX® in the U.S. and
Xiapex® in Europe, today announced that
management will present a corporate overview at the upcoming
Jefferies 2017 Healthcare Conference on Friday, June 9, 2017 at 12:30 p.m. ET in New
York, NY.
A live webcast of the presentation can be accessed under "Events
and Presentation" in the Investors section of the Company's website
at www.biospecifics.com or at
http://wsw.com/webcast/jeff105/bstc.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company
that has developed injectable collagenase for thirteen clinical
indications to date. Injectable collagenase is marketed as
XIAFLEX® in the U.S. for the treatment of
Dupuytren's contracture and Peyronie's disease by BioSpecifics'
partner, Endo International plc (Endo). XIAFLEX® is
also commercialized
in Japan, Europe, Canada and Australia for
Dupuytren's contracture and for Peyronie's disease in Europe
and Australia. Endo is partnered with Sobi, Actelion and Asahi
Kasei for Dupuytren's contracture and Peyronie's disease outside
the U.S. The XIAFLEX research and development pipeline includes
several additional promising indications. BioSpecifics is managing
the development of XIAFLEX for uterine fibroids and is conducting a
Phase 1 clinical trial. For more information, please
visit www.biospecifics.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-the-jefferies-2017-healthcare-conference-300468099.html
SOURCE BioSpecifics Technologies Corp.